1 Early start of oral clarithromycin is associated with better outcome in COVID-19 2 of moderate severity: the ACHIEVE open-label trial

3

4 Running title: Clarithromycin in COVID-19

5

6 Konstantinos Tsiakos¹, Antonios Tsakiris^{2*}, Georgios Tsibris^{2*},

7 Pantazis Voutsinas^{2*}, Periklis Panagopoulos³, Maria Kosmidou⁴,

8 Vasileios Petrakis³, Areti Gravvani¹, Theologia Gkavogianni²,

9 Eleftherios Klouras⁴, Konstantina Katrini², Panagiotis Koufargyris², Iro Rapti⁴,

10 Athanassios Karageorgos², Emmanouil Vrentzos², Christina Damoulari²,

11 Vagia Zarkada², Chrysanthi Sidiropoulou⁵, Sofia Artemi², Anastasios Ioannidis⁶,

12 Androniki Papapostolou², Evangelos Michelakis², Maria Georgiopoulou²,

13 Dimitra-Melia Myrodia¹, Panteleimon Tsiamalos⁵, Konstantinos Syrigos¹,

14 George Chrysos⁵, Thomas Nitsotolis¹, Haralampos Milionis⁴,

15 Garyphallia Poulakou¹, Evangelos J. Giamarellos-Bourboulis¹

16

17 *equal contribution

18

19 ¹3rd Department of Internal Medicine, National and Kapodistrian University of Athens,
20 Medical School, 115 27 Athens, Greece;

21 ²4th Department of Internal Medicine, National and Kapodistrian University of Athens,
22 Medical School, 124 62 Athens, Greece;

23 ³2nd Department of Internal Medicine, Democritus University of Thrace, Medical
24 School, 681 00 Alexandroupolis, Greece;

1 ⁴1st Department of Internal Medicine, University of Ioannina, School of Health
2 Sciences, Faculty of Medicine, 455 00 Ioannina, Greece
3 ⁵2nd Department of Internal Medicine, Tzaneion General Hospital of Piraeus, Greece
4 ⁶Department of Nursing, Faculty of Health Sciences, University of Peloponnese,
5 Tripoli, Greece
6

7 **Conflicts of Interest statement**

8 P. Panagopoulos has received honoraria from GILEAD Sciences, Janssen, and
9 MSD.

10 G. Poulakou has received independent educational grants from Pfizer, MSD,
11 Angelini, and Biorad.

12 H. Milionis reports receiving honoraria, consulting fees and non-financial support
13 from healthcare companies, including Amgen, Angelini, Bayer, Mylan, MSD, Pfizer,
14 and Servier.

15 E.J. Giamarellos-Bourboulis has received honoraria from Abbott CH, Angelini Italy,
16 InflaRx GmbH, MSD Greece, XBiotech Inc., and B·R·A·H·M·S GmbH (Thermo Fisher
17 Scientific); independent educational grants from AbbVie Inc, Abbott CH, Astellas
18 Pharma Europe, AxisShield, bioMérieux Inc, Novartis, InflaRx GmbH, Sobi and
19 XBiotech Inc; and funding from the FrameWork 7 program HemoSpec (granted to the
20 National and Kapodistrian University of Athens), the Horizon2020 Marie-Curie Project
21 European Sepsis Academy (granted to the National and Kapodistrian University of
22 Athens), and the Horizon 2020 European Grant ImmunoSep (granted to the Hellenic
23 Institute for the Study of Sepsis).

24 The other authors do not report any conflict of interest.

25

1 **Funding statement**

2 This work was supported by Abbott Operation Products AG. Funding body had no
3 role in the design, conduct, analysis and interpretation of data, and decision to
4 publish.

5

6 **Corresponding Author**

7 Evangelos J. Giamarellos-Bourboulis, MD, PhD

8 4th Department of Internal Medicine,

9 ATTIKON University General Hospital

10 1 Rimini Street 124 62 Athens, Greece

11 Tel: +30 210 58 31 994

12 Fax: +30 210 53 26 446

13 E-mail: egiamarel@med.uoa.gr

14

15 **Abstract word count:** 197

16 **Text word count:** 3,007

17

18

19

20

21

22

23

24

25

1 ABSTRACT

2 **Background:** To study the efficacy of oral clarithromycin in moderate COVID-19.

3 **Methods:** An open-label non-randomized trial in 90 patients with COVID-19 of
4 moderate severity was conducted between May and October 2020. The primary
5 endpoint was defined at the end-of-treatment (EOT) as no need for hospital re-
6 admission and no progression into lower respiratory tract infection (LRTI) for patients
7 with upper respiratory tract infection; and as at least 50% decrease of the respiratory
8 symptoms score the without progression into severe respiratory failure (SRF) for
9 patients with LRTI. Viral load, biomarkers, the function of mononuclear cells, and
10 safety were assessed.

11 **Results:** The primary endpoint was attained in 86.7% of patients treated with
12 clarithromycin (95% CIs 78.1-92.2%); this was 91.7% and 81.4% among patients
13 starting clarithromycin the first 5 days from symptoms onset or later (odds ratio after
14 multivariate analysis 6.62; p: 0.030). The responses were better for patients infected
15 by non-B1.1 variants. Clarithromycin use was associated with decreases in
16 circulating C-reactive protein, tumour necrosis factor-alpha and interleukin (IL)-6; by
17 increase of Th1 to Th2 mononuclear responses; and by suppression of SARS-CoV-2
18 viral load. No safety concerns were reported.

19 **Conclusions:** Early clarithromycin treatment provides most of clinical improvement
20 in moderate COVID-19 (**Trial Registration:** ClinicalTrials.gov, NCT04398004)

21

22 **Key-words:** clarithromycin; COVID-19; Th1; Th2; viral load

23

24

25

1 INTRODUCTION

2 Early at the beginning of the COVID-19 pandemic azithromycin, a macrolide
3 drug was introduced in the treatment algorithm due to its anti-inflammatory properties
4 [1, 2]. The anti-inflammatory properties of macrolides for the empirical management
5 of community-acquired pneumonia (CAP) are reflected in the guidelines of the
6 American Thoracic Society published in 2019 [3]. These guidelines are influenced by
7 observational studies showing that the addition of a macrolide decreases the risk of
8 death from severe CAP [4-8]. Two double-blind, randomized, placebo-controlled
9 clinical trials of our group have also shown substantial reduction of the risk of death
10 among critically ill patients with Gram-negative sepsis and ventilator-associated
11 pneumonia with clarithromycin adjunctive treatment [9-11]. We have also recently
12 shown that 28-day mortality of severe CAP was 20.8% among patients treated with a
13 combination of β -lactam and clarithromycin and 33.8% when treated with a
14 combination of β -lactam and azithromycin [12].

15 Based on the above evidence, it seems likely that treatment of COVID-19 with
16 oral clarithromycin may attenuate the hyper-inflammatory responses of the host and
17 decrease the risk of progression into SRF. We conducted the ACHIEVE trial (Anti-
18 inflammatory Clarithromycin to Improve SARS-CoV 2 Infection Early) to investigate
19 whether early administration of oral clarithromycin in patients with upper or lower
20 respiratory tract infection (RTI) due to SARS-CoV-2, may attenuate the inflammatory
21 burden, modulate the immune response of the host and result in early clinical
22 improvement. The primary objective was to investigate the clinical response after
23 early start of treatment. The efficacy of clarithromycin was also compared with a
24 group of propensity-score matched concurrent comparators receiving standard-of-
25 care treatment (SOC) with azithromycin and hydroxychloroquine.

1 PATIENTS AND METHODS

2 Patient population

3 ACHIEVE was an open-label non-randomized trial conducted in four study
4 sites in tertiary hospitals in Greece (EudraCT number 2020-001882-36; National
5 Ethics Committee approval 45/20; National Organization for Medicines approval ISO
6 36/20; ClinicalTrials.gov NCT04398004). Concurrent comparators receiving
7 azithromycin plus hydroxychloroquine/chloroquine were hospitalized at the same
8 time period in five other medical departments of tertiary hospitals of Greece. Written
9 informed consent was provided by the patient or legal representative before
10 screening.

11 Enrolled patients were adults (age ≥ 18 years) with confirmed infection by
12 SARS-CoV-2 virus by real-time PCR of nasopharyngeal secretions; and infection of
13 the upper respiratory tract (URTI) or of the lower respiratory tract (LRTI). URTI was
14 defined as the acute presentation of at least two of the following signs in a patient
15 without radiological evidence of lung infection: a) core temperature $\geq 37.5^{\circ}\text{C}$; b) new
16 onset of cough; c) chills or rigor; and d) total absolute lymphocyte count less than
17 $1,500/\text{mm}^3$. LRTI was defined as the presence of infiltrates compatible with lower
18 respiratory tract infections in chest X-ray or in chest computed tomography
19 accompanied by at least one of the following: a) new onset of cough or worsening
20 cough; b) dyspnea; c) respiratory rates compatible with lung infection; and d) total
21 absolute lymphocyte count less than $1,500/\text{mm}^3$. Exclusion criteria were: age below
22 18 years; intake of any other macrolide and of hydroxychloroquine/chloroquine for
23 the infection under study; ratio of partial oxygen pressure to the fraction of inspired
24 oxygen (pO_2/FiO_2) less than 150; need for mechanical ventilation (MV) or non-
25 invasive ventilation under positive pressure (NIV); neutropenia ($<1,000/\text{mm}^3$); any

1 intake of corticosteroids at a daily dose $\geq 0.4\text{mg/kg}$ prednisone or equivalent the last
2 15 days; QTc interval at rest electrocardiogram ≥ 500 msec; and pregnancy or
3 lactation.

4 In order to derive the most appropriate comparators, the inclusion and
5 exclusion criteria of the ACHIEVE trial were applied to all available concurrent
6 comparators.

7

8 **Trial interventions**

9 Enrolled patients received one tablet of 500 mg of clarithromycin every 12
10 hours for 7 days. All other drugs except macrolides and hydroxychloroquine/
11 chloroquine phosphate were allowed. Study visits were done daily starting from day 1
12 before start of treatment until day 8 after end of treatment (EOT visit). The test-of-
13 cure (TOC) visit was done on day 14. For patients discharged earlier from hospital,
14 EOT and TOC visits were done by phone calls. Recorded baseline information was
15 severity assessed by APACHE II score, SOFA score and pneumonia severity index
16 (PSI), comorbidities and laboratory information. On each visit follow-up, the state of
17 the patient was assessed and the respiratory symptoms score (RSS) was calculated
18 (see Supplementary methods). Fifteen ml of whole blood was collected on day 1
19 before start of treatment and on EOT into EDTA-coated tubes and sterile and
20 pyrogen-free tubes for the isolation of peripheral blood mononuclear cells (PBMCs),
21 serum and plasma. PBMCs were isolated after gradient centrifugation over Ficoll
22 (Biochrom, Berlin, Germany) for 20 minutes at 1400g. After three washings in ice-
23 cold PBS pH 7.2, PBMCs were counted in a Neubauer plate with trypan blue
24 exclusion of dead cells. They were then diluted in RPMI 1640 enriched with 2mM of
25 L-glutamine, 500 $\mu\text{g/ml}$ of gentamicin, 100 U/ml of penicillin G, 10 mM of pyruvate,

1 10% fetal bovine serum (Biochrom) and suspended in wells of a 96-well plate. The
2 final volume per well was 200µl with a density of 2×10^6 cells/ml. PBMCs were
3 exposed in duplicate for 24 hours or 5 days at 37°C in 5% CO₂ to different stimuli: 10
4 ng/ml of *Escherichia coli* O55:B5 lipopolysaccharide (LPS, Sigma, St. Louis, USA) or
5 5×10^5 colony forming units of heat-killed *Candida albicans*. Following incubation, cells
6 were removed and analysed for flow cytometry. Concentrations of tumour necrosis
7 factor-alpha (TNFα), interleukin (IL)-6, IL-10 and interferon-gamma (IFNγ) were
8 measured in cell supernatants or serum in duplicate by an enzyme immunoassay;
9 the lower limit of detection was 20 pg/ml (Invitrogen, Carlsbad, California, USA). C-
10 reactive protein was measured by nephelometry; the lower limit of detection was 0.5
11 mg/l.

12 Nasopharyngeal swabs were collected using the 350C UTM© mini 1ml
13 collection and transport system (COPAN, Italia, S.p.A.) on day 1 before start of
14 treatment, on day 4 and on EOT. The viral load was expressed as the Ct of the
15 reaction positivity and as the relative log2 copies of the *E* gene and of the *RdRp*
16 gene. Viral RNA was extracted from the transport medium using the QIAamp® Viral
17 RNA Mini kit (Qiagen, Hilden, Germany) and all quantified with the Qubit™ RNA HS
18 Assay Kit on a Qubit Fluorometer (Thermo Fisher Scientific Waltham, MA USA).
19 Sequencing libraries were generated using the CleanPlex® SARS-CoV-2 Research
20 and Surveillance Panel powered by SOPHiA (Paragon Genomics, Hayward, CA,
21 USA) using CleanPlex Indexed PCR Primers for Illumina (Paragon Genomics). The
22 generated DNA libraries were loaded in a 300-cycle sequencing cartridge and
23 sequenced on an Illumina MiSeq platform (Illumina, San Diego, CA, USA).

24 The generated analysis output, in the FASTQ file format, was uploaded to the
25 SOPHiA DDM tool (SOPHiA GENETICS Inc, Boston, MA, USA). A total of 5,598,884

1 read pairs were generated of which 5,351,919 pairs (95.59%) were successfully
2 mapped. The reference sequence used was MN908947 (NC_045512.2). Four quality
3 indicators generated for all samples (coverage uniformity <90%, effective reads
4 <90%, pool 1 and 2 balance <-1 and >1 log 2 ratio, target covered <95%) allow easy
5 assessment of sequencing results quality. The genome sequences of SARS-CoV-2
6 were assigned to viral lineages according to the dynamic nomenclature system
7 proposed by Rambaut et al [13] using the SOPHiA DDM tool ([https://pangolin.cog-](https://pangolin.cog-uk.io)
8 [uk.io](https://pangolin.cog-uk.io)).

9 Blood was sampled from concurrent SOC comparators on day 1 before start
10 of treatment and on day 8 for the measurement of biomarkers.

11

12 Outcomes

13 The primary study endpoint was assessed at EOT and it was a composite
14 endpoint defined differently for patients with URTI and for patients with LRTI. For
15 patients with URTI the primary endpoint was defined as either no need for hospital
16 re-admission in case of earlier discharge or as lack of progression into lower RTI. For
17 patients with LRTI the primary endpoint was defined as any least 50% decrease of
18 the RSS from the baseline provided that the patient has not progressed into SRF or
19 died. SRF was defined as any decrease of the pO₂/FiO₂ below 150 mmHg
20 necessitating MV or NIV. This end point was compared between patients who started
21 early and those who started late clarithromycin. The same endpoints were captured
22 for the SOC concurrent comparators. Secondary outcomes were the development of
23 SRF by TOC visit; hospital readmission until TOC; the change of viral load from
24 baseline in respiratory secretions on day 4 and EOT; the change of circulating
25 biomarkers; and the changes of cytokine responses. Study exploratory endpoints

were the impact of time delay from the onset of COVID-19 symptoms on the change of the 11-point WHO clinical progression scale [14]; and the association with the lineage of SARS-CoV-2.

Similar definitions of the study endpoints were applied for concurrent SOC comparators. Adverse Events (AE) (Common Terminology Criteria for Adverse Events, version 4.03) and Severe Adverse Events (SAE) (see Supplementary Appendix) were captured.

Statistical analysis

Qualitative data were presented as percentages with confidence intervals (CI) and quantitative data as means and SD; biomarkers and cytokines were expressed as means and SE. Using the median of the time between symptoms onset and start of clarithromycin, patients were divided into those with an early start and into those with a late start; comparisons were done by the binomial test. Propensity score 1:1 matching was applied to select the best matched comparators to the 90 patients treated with clarithromycin. Matching variables were: age, Charlson's comorbidity index (CCI), admission PSI; the frequency of URTI and LRTI; and admission C-reactive protein (CRP). Comparisons were performed by the Fisher's exact test using confirmatory forward stepwise logistic regression analysis (IBM SPSS Statistics v. 25.0). Paired comparisons were done by the Wilcoxon's signed rank test. Any two-sided P value <0.05 was statistically significant.

1 RESULTS

2 Trial conduct

3 Patients participating in the ACHIEVE open-label trial were enrolled between
 4 May 17 2020 and October 8 2020. After propensity matching, 90 concurrent SOC
 5 comparators were selected within the same time frame. The propensity score of
 6 patients enrolled in the ACHIEVE trial was 0.357 ± 0.094 ; the respective score of the
 7 concurrent SOC comparators was 0.360 ± 0.099 (P: 0.829). The study flow chart is
 8 shown in supplementary Figure 1. None of the 180 participants received biological
 9 anti-cytokine drugs. The administered dose of azithromycin was 500mg daily for
 10 seven days and of hydroxychloroquine 500 mg every 12 hours for seven days.
 11 Baseline demographics of patients receiving clarithromycin and of concurrent
 12 comparators are shown in supplementary Table 1. No difference was found between
 13 the two groups.

14

15 Study endpoints

16 The primary endpoint was met in 78 patients treated with clarithromycin
 17 (86.7% 95% CIs 78.1-92.2%). Using the median of distribution, patients treated with
 18 clarithromycin were divided into those who started treatment within the first 5 days
 19 from start of symptoms (n= 48, range 1-5 day) and into those who started treatment 6
 20 days or later from start of symptoms (n= 42, range 6-12 days). No differences were
 21 found in baseline characteristics of the enrolled patients divided into those with early
 22 and late start of clarithromycin (Table 1). The primary endpoint was achieved in
 23 91.7% (44 out of 48 patients; 95% CIs 80.4-96.7%) and in 81.4% (34 out of 42
 24 patients; 95% CIs 66.7-90.0%) respectively (P: 0.021). This finding was confirmed
 25 after multivariate logistic regression analysis showing early start of clarithromycin to

1 be the only independent variable to be positively associated with the favourable
2 primary endpoint (Table 2).

3 RSS was significantly decreased within the first 24 hours from start of
4 clarithromycin (supplementary Figure 2).

5 The change of baseline (before start of the study drug) viral load on day 4 of
6 treatment with clarithromycin and at the EOT visit with clarithromycin are shown in
7 Figure 1. The time of Ct to positivity was increased over study visits so as to be
8 considered as indirect index of the decrease of the copies of *E* gene and *RdRp* gene.
9 The relative log2 copies of both genes were decreased over-time.

10 NGS analysis of viral isolates did not detect any single nucleotide variant
11 (SNV) in either the *E* gene or in the *RdRp* gene. SARS-CoV-2 viral isolates could be
12 determined following quality control amputation in isolates coming from 49 patients.
13 In total, analysis included 32 viral isolates of the B1.1 lineage and 17 isolates of the
14 non-B.1.1 lineage. Patients starting early clarithromycin had an achievement of the
15 positive primary endpoint of treatment response similar for both types of viral lineage.
16 However, among patients starting late clarithromycin the achievement of the positive
17 treatment response was significantly greater among those infected by the non-B1.1
18 SARS-CoV-2 viral isolates (Table 3).

19 Clarithromycin treatment was associated with increased Th1 responses
20 reflected from the increase of the targeted production of IFN γ using stimulation with
21 heat-killed *C.albicans* for 5 days (Figure 2A). It was also associated with an
22 attenuation of the Th2 responses as reflected by the targeted production of IL-6
23 (Figure 2B). The ratio of Th1/Th2 response from PBMCs at the EOT was greater
24 among patients with lower viral load (Figures 2C and 2D). On the contrary, no
25 change of the monocyte function was found (supplementary Figure 3).

1 The selection of SOC concurrent comparators was appropriate and no
2 differences in baseline characteristics were found (supplementary Table 1). The
3 primary endpoint was met in 66 patients among the concurrent SOC comparators
4 (73.3%; 95% CIs; 63.4-81.4%) and this was significantly lower than patients treated
5 with clarithromycin. When concurrent SOC comparators and patients treated with
6 clarithromycin were analyzed as one cohort, clarithromycin treatment and nine other
7 variables showed an association with the endpoint in univariate logistic regression.
8 However, in a multivariate step-wise logistic regression analysis, only three variables
9 retained a robust independent association with the endpoint (Table 4), including
10 clarithromycin treatment (odds ratio 3.30; 95% CIs 1.10-9.87; P: 0.033).

11 Clarithromycin treatment was associated with attenuation of pro-inflammatory
12 responses. On day 8 the serum concentrations of C-reactive protein (CRP), tumour
13 necrosis factor-alpha (TNF α) and interleukin (IL)-6 were lower among patients
14 treated with clarithromycin than among concurrent SOC comparators. No differences
15 were found in IL-10 (Figure 3).

16 At the TOC visit, the incidence of SRF was 12.2% (n= 11; 95% CIs 6.9-20.6%)
17 among patients treated with clarithromycin. This was 26.7% (n= 24; 95% CIs 18.6-
18 36.6%) among SOC concurrent comparators (P: 0.023). Multivariate logistic
19 regression analysis revealed that the only independent variable associated with
20 protection from SRF at TOC was the intake of clarithromycin (odds ratio 0.22; 95%
21 CIs 0.06-0.79; P: 0.022; supplementary Table 2).

22 The benefit coming from the early start of clarithromycin was reflected on the
23 exploratory outcome of the 11-point WHO CPS by day 28. The decrease of points of
24 the scale of symptoms was significantly greater among early starters of
25 clarithromycin (supplementary Figure 4).

1 **Safety**

2 The serious adverse events (SAEs) and the non-serious AEs that were
3 captured during the study period of 14 days are listed in supplementary Table 3.
4 Reported events probably or possibly-related to the study drug with incidence greater
5 than 1% were: increase of aminotransferases (Grade I 18.8%; Grade II 1.1%);
6 diarrhea (mild 12.1%; moderate 1.1%); mild vomiting in 1.1%, Grade I increase of
7 bilirubin in 2.22%; and mild allergic reaction in 1.1%). No drug-related SAEs were
8 reported.

9

10 **DISCUSSION**

11 Based on previous experience with clarithromycin [9-12], we sought to
12 investigate its potential in reducing the hyper-inflammatory response in moderate
13 COVID-19 and contribute to better clinical outcomes than currently available
14 treatment approaches. Analysis revealed that clarithromycin treatment was
15 associated with a significantly greater clinical benefit at the EOT visit of 86.7%, as
16 compared with 73.3% achieved by the concurrent SOC comparators. This early
17 benefit shown at the end of the 7-day course with clarithromycin was further reflected
18 in the incidence of SRF at the TOC visit of day 14, when treatment with
19 clarithromycin provided 78% relative decrease of the risk for SRF compared to the
20 SOC regimen. The benefit was pronounced for patients starting clarithromycin within
21 the first 5 days from the onset of Covid-19-related symptoms. The benefit of
22 clarithromycin was also linked with decrease of CRP and IL-6 at the EOT.

23 Emerging data suggest that active virus replication and persistence in the
24 upper respiratory tissue are associated with the severity of the illness [15, 16].
25 Patients treated with clarithromycin showed remarkable reduction of the viral load in

1 the nasopharynx which was associated with clinical improvement. At the end of
2 treatment with clarithromycin, the Th1 cell responses were increased whereas the
3 Th2 cell responses were attenuated. The Th1 cells are responsible for the
4 containment of the viral replication in viral infections. Specifically, in COVID-19 the
5 inhibition of the Th1-mediated immune responses has a critical impact on the viral
6 replication and the severity of the illness [17]. Patients with lower viral load at the
7 EOT visit had greater Th1/Th2 ratio as this was expressed by modulation of the
8 production of IFN γ and of IL-6 by circulating lymphocytes.

9 The findings of the ACHIEVE study should be interpreted in the light of certain
10 limitations. The study was designed in mid-March 2020 at the beginning of the
11 pandemic in Greece. It was decided to endorse an open-label and single-arm design
12 in an attempt to include (and benefit) as many patients as possible since no SOC
13 was framed at that time period. The azithromycin plus hydroxychloroquine concurrent
14 comparators were optimally matched without differences in baseline severity and co-
15 administered treatment. When the study was started, most of the patients with
16 COVID-19 hospitalized in the Greek Hospitals were co-administered azithromycin
17 and hydroxychloroquine as an off-label treatment option. In the following months,
18 emerging data showed that hydroxychloroquine does not affect the natural course of
19 COVID-19 [18, 19]. As such, the comparison between the clarithromycin group and
20 the azithromycin plus hydroxychloroquine group should be conceived as comparison
21 between clarithromycin and azithromycin.

22 In the randomized COALITION trial from Brazil, patients with moderate to
23 severe COVID-19 were randomized to treatment with placebo (n=227),
24 hydroxychloroquine (n=221) and a combination of hydroxychloroquine and
25 azithromycin (n=217). The achievement of the primary endpoint was similar between

the three groups of treatment [20]. The same group of investigators performed the COALITION II trial where patients were allocated to treatment with standard-of-care with (n=214) or without azithromycin (n=183). Although the two groups did not differ in the achievement of the primary endpoint after 15 days, patients allocated to azithromycin treatment had a better overall health state after 7 days of treatment [21].

In conclusion, the results of the ACHIEVE trial clearly indicate that clarithromycin treatment in patients with moderate COVID-19 is associated with early clinical improvement and containment of viral load. This is associated with an increase of the ratio of Th1/Th2 response. To the best of our knowledge this is the first study to show the anti-inflammatory impact of clarithromycin on COVID-19. Further studies are needed to better define its future role in mild and moderate COVID-19.

Acknowledgements

We would like to thank Hughes associates, Oxford, UK for supporting us with manuscript preparation. The authors would like to thank the patients, families, clinical, laboratory and research staff who contributed to the trial.

1 REFERENCES

- 2 1. Giamarellos-Bourboulis EJ, Netea MG, Rovina N, et al. Complex immune
3 dysregulation in COVID-19 patients with severe respiratory failure. *Cell Host*
4 *Microbe* **2020**; 27: 992-1000.
- 5 2. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a
6 treatment of COVID-19: results of an open-label non-randomized clinical trial. *Int*
7 *J Antimicrob Agents* **2020**; 56: 105949.
- 8 3. Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with
9 community-acquired pneumonia. *Am J Resp Crit Care Med* **2019**; 200: 45-67.
- 10 4. García Vázquez E, Mensa J, Martínez JA, et al. Lower mortality among patients
11 with community-acquired pneumonia treated with a macrolide plus a beta-lactam
12 agent versus a beta-lactam agent alone. *Eur J Clin Microbiol Infect Dis*, **2005**; 24:
13 190-5.
- 14 5. Metersky ML, Ma A, Houck PM, Bratzler DW. Antibiotics for bacteremic
15 pneumonia: improved outcomes with macrolides but not fluoroquinolones. *Chest*
16 **2007**; 131: 466-73.
- 17 6. Restrepo MI, Mortensen EM, Waterer GW, Wunderink RG, Coalson JJ, Anzueto
18 A. Impact of macrolide therapy on mortality for patients with severe sepsis due to
19 pneumonia. *Eur Resp J* **2009**; 33: 153-9.
- 20 7. Martin-Loeches I, Lisboa T, Rodriguez A, et al. Combination antibiotic therapy
21 with macrolides improves survival in intubated patients with community-acquired
22 pneumonia. *Intensive Care Med* **2010**; 36: 612-20.
- 23 8. Nie W, Li B, Xiu Q. β -Lactam/macrolide dual therapy versus β -lactam
24 monotherapy for the treatment of community-acquired pneumonia in adults: a
25 systematic review and meta-analysis. *J Antimicrob Chemother* **2014**; 69: 1441-6.

- 1 9. Giamarellos-Bourboulis EJ, Pechère JC, Routsis C, et al. Effect of clarithromycin in
2 patients with sepsis and ventilator-associated pneumonia. Clin Infect Dis **2008**;
3 46: 1157-64.
- 4 10. Giamarellos-Bourboulis EJ, Mylona V, Antonopoulou A, et al. Effect of
5 clarithromycin in patients with suspected Gram-negative sepsis: results of a
6 randomized controlled trial. J Antimicrob Chemother **2014**; 69: 1111-8.
- 7 11. Tsaganos T, Raftogiannis M, Pratikaki M, et al. Clarithromycin leads to long-term
8 survival and cost benefit in ventilator-associated pneumonia and sepsis.
9 Antimicrob Agents Chemother **2016**; 60: 3640-6.
- 10 12. Kyriazopoulou E, Sinapidis D, Halvatzis S, et al. Survival benefit associated with
11 clarithromycin in severe community-acquired pneumonia: a matched comparator
12 study. Int J Antimicrob Agents **2020**; 55: 105836.
- 13 13. Rambaut A, Holmes EC, O'Toole Á, et al. A dynamic nomenclature proposal for
14 SARS-CoV-2 lineages to assist genomic epidemiology. Nat Microbiol **2020**; 5:
15 1403-7.
- 16 14. WHO working group on the clinical characterization and management of COVID-
17 19 infection. A minimal common outcome measure set for COVID-19 clinical
18 research. Lancet Infect Dis **2020**; 20: e192-7.
- 19 15. Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized
20 patients with COVID-2019. Nature **2020**; 581: 465-9.
- 21 16. Zheng S, Fan J, Yu F, et al. Viral load dynamics and disease severity in patients
22 infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020:
23 retrospective cohort study. BMJ **2020**; 369: m1443.
- 24 17. Toor SM, Saleh R, Sasidharan Nair V, Taha RZ, Elkord E. T-cell responses and
25 therapies against SARS-CoV-2 infection. Immunology **2021**; 162: 30-43.

- 1 18. Self WH, Semler MW, Leither LM, et al. Effect of hydroxychloroquine on clinical
2 status at 14 days in hospitalized patients with COVID-19: a randomized clinical
3 trial. JAMA **2020**; 324: 2165-76.
- 4 19. Kashour Z, Riaz M, Garbati MA, et al. Efficacy of chloroquine or
5 hydroxychloroquine in COVID-19 patients: a systematic review and meta-
6 analysis. J Antimicrob Chemother **2021**; 76: 30-42.
- 7 20. Cavalcanti AB, Zampieri FG, Rosa RG, et al. Hydroxychloroquine with or without
8 azithromycin in mild-to-moderate Covid-19. N Engl J Med **2020**; 38: 2041-52.
- 9 21. Furtado RHM, Berwanger O, Fonseca HA, et al. Azithromycin in addition to
10 standard of care versus standard of care alone in the treatment of patients
11 admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a
12 randomized clinical trial. Lancet **2020**; 396: 959-67.

13
14
15
16
17
18
19
20
21
22
23
24
25

1 **Figure legends**

2

3 **Figure 1 Viral loads of *E* gene and *RdRp* gene in the nasopharynx**

4 Viral load of SARS-CoV-2 was assessed in the nasopharynx of clarithromycin-treated
5 patients over visit using the relative expression of the constitutive *E* gene and of the
6 specific *RdRp* gene. The expression of both genes was expressed as both the
7 absolute time cycle (Ct) of the real-time PCR reaction and the log2 relative copies.
8 The arrows indicate the comparisons; the respective P-value by the Wilcoxon rank-
9 sum test is provided

10 Abbreviation EOT: end-of-treatment

11

12 **Figure 2 The increase of Th1 response at the end-of-treatment as the proposed** 13 **mechanism of action of clarithromycin**

14 Production of A) interferon-gamma (IFN γ) reflecting Th1 response; and of B)
15 interleukin (IL)-6 reflecting Th2 response from isolated peripheral blood mononuclear
16 cells following stimulation with heat-killed *Candida albicans* before start of treatment
17 with clarithromycin and at end-of treatment (EOT) with clarithromycin.

18 Comparison of the Th1/Th2 ratio of PBMCs at the EOT between patients with high
19 and low viral load of SARS-CoV-2 on the same treatment visit. The viral load is
20 expressed as the Ct of positivity of the real-time PCR separately for C) the *E* gene
21 and for D) the *RdRp* gene. The N values in parenthesis refer to the existing number
22 of patients analysed.

23 The P-values of comparisons by the Mann-Whitney U-test are provided.

24

Figure 3 Attenuation of pro-inflammatory responses in COVID-19 following treatment with clarithromycin

Serum concentrations of C-reactive protein (CRP), of tumour necrosis factor-alpha (TNFα) and of interleukin (IL)-6 were measured before start of treatment and at the end-of-treatment visit (EOT) of day 8 among patients treated with clarithromycin (ACHIEVE trial) and among concurrent standard-of-care (SOC) comparators. The P-values of comparisons by the Mann-Whitney U test are provided.

Abbreviation EOT: end-of-treatment

- 1 **Table 1 Baseline lab values and treatment modalities for participants in the**
- 2 **ACHIEVE trial.** Patients are divided onto those who started early treatment with
- 3 clarithromycin (5 days or less from symptoms onset) and into those who started late
- 4 treatment with clarithromycin (6 days or more from symptoms onset)

Variable	Late start (N=42)	Early start (N=48)	P- Value
Age, years, mean (SD)	57.0 (17.4)	58.5 (16.9)	0.959
Male gender, n (%)	24 (57.1)	29 (60.4)	0.831
Upper/lower respiratory tract infection, n (%)	5 (11.9)/37 (88.1)	7 (14.6)/41 (85.4)	0.765
Severity indexes, mean (SD)			
Charlson's Comorbidity Index	2.50 (2.68)	2.29 (2.20)	0.687
Admission APACHE II score	5.28 (3.97)	5.70 (3.33)	0.604
Admission Pneumonia Severity Index	60.3 (27.9)	60.1 (27.1)	0.966
Admission SOFA score	1.14 (1.09)	1.33 (1.26)	0.449
Comorbidities, no. (%)			
Type 2 diabetes mellitus	6 (14.3)	11 (22.9)	0.419
Chronic heart failure	2 (4.8)	2 (4.2)	1.00
Coronary heart disease	4 (9.5)	4 (8.3)	1.00
Chronic renal disease	1 (2.4)	5 (10.4)	0.209
Atrial fibrillation	3 (7.1)	0 (0)	0.098
Hypertension	17 (40.5)	19 (39.6)	1.00
Chronic obstructive pulmonary disease	1 (2.4)	3 (6.3)	0.620
Hypothyroidism	6 (14.3)	6 (12.5)	1.00
Solid tumor malignancy	5 (11.9)	2 (4.2)	0.245
Dyslipidemia	11 (26.2)	11 (22.9)	0.808

Laboratory values, mean (SD)

Total white blood cells (/mm ³)	5930.7 (1700.1)	6159.1 (2716.3)	0.642
Neutrophils (/mm ³)	3835.7 (1674.5)	4370.6 (2528.5)	0.251
Lymphocytes (/mm ³)	1331.7 (574.7)	1336.2 (491.5)	0.968
Platelets (x 10 ³ /mm ³)	221.4 (83.7)	208.8 (61.6)	0.424
International normalized ratio	1.10 (0.25)	1.10 (0.21)	0.887
AST (U/l)	33.9 (16.2)	34.1 (24.7)	0.984
ALT (U/l)	30.6 (14.9)	34.6 (26.2)	0.395
pO ₂ /FiO ₂ (mmHg)	373.7 (103.3)	370.6 (72.8)	0.872
C-reactive protein (mg/l)	77.2 (108.4)	62.7 (58.3)	0.439

Concomitant treatment, n (%)

3 rd -generation cephalosporin	27 (64.3)	36 (76.6)	0.246
Piperacillin/tazobactam	7 (16.7)	4 (8.5)	0.337
Moxifloxacin/levofloxacin	1 (2.4)	1 (2.1)	1.00

1

2 Abbreviations: ALT: alanine aminotransferase; APTT: activate partial thromboplastin
3 time; AST: aspartate aminotransferase; APACHE: acute physiology and chronic
4 health evaluation; no: number; pO₂/FiO₂: ratio of partial oxygen pressure to the
5 fraction of inspired oxygen; SOFA: sequential organ failure assessment; SD:
6 standard deviation

7

8

9

Table 2 Univariate and multivariate logistic regression analysis of baseline variables associated with the achievement of the study primary endpoint in the ACHIEVE trial.

Variable	Incidence of primary endpoint		Univariate analysis		Multivariate analysis	
	No (total=12)	Yes (total=78)	OR (95% CIs)	P	OR (95% CIs)	P
Start of clarithromycin within the first 5 days for symptoms onset, n (%)	4 (33.3)	44 (56.4)	3.49 (0.85-14.34)	0.082	6.62 (1.19-32.63)	0.030
CCI, mean (SD)	4.00 (2.95)	2.14 (2.25)	0.76 (0.60-0.96)	0.019	*	
Admission APACHE II score, mean (SD)	8.00 (3.13)	5.12 (3.79)	0.84 (0.72-0.97)	0.021	*	
Admission SOFA score, mean (SD)	2.16 (1.11)	1.10 (1.13)	0.51 (0.31-0.84)	0.008	0.39 (0.22-0.68)	0.001
Admission PSI, mean (SD)	80.7 (20.7)	57.0 (26.9)	0.97 (0.95-0.99)	0.008	*	
Lymphocytes/mm ³ , mean (SD)	1126.9 (432.3)	1366.5 (536.9)	1.00	0.148		
CRP, mg/l, mean (SD)	110.1 (180.2)	63.7 (61.4)	0.99 (0.99-1.00)	0.094	*	

*variable did not enter the equation after three steps of the multivariate model

Abbreviations APACHE: acute physiology and chronic health evaluation; CCI: Charlson's comorbidity index; CI: confidence interval;

CRP: C-reactive protein; OR: odds ratio; PSI: pneumonia severity index; SOFA: sequential organ failure assessment

Table 3 Association between delay start of clarithromycin and onset of symptoms and lineage of SARS-CoV-2 viral isolate and achievement of the primary treatment outcome

Achievement of primary endpoint	Non-B1.1 lineage*, n (%)	B1.1 lineage, n (%)	P-value	OR (95%CI)
Early start of clarithromycin (≤ 5 days)				
No	1 (14.3)	2 (9.5)	1.00	1.58
Yes	6 (85.7)	19 (90.5)		0.12-20.69
Late start of clarithromycin (> 5 days)				
No	0 (0)	5 (45.5)	0.035	NC**
Yes	10 (100)	6 (54.5)		

*Isolates were matched as B1.1 (n= 30, 61.2%); B1.1. with 75% matching to the parent B1.1 (n= 2, 4.1%); B1.1. with 50% matching to the parent B1.1 (n= 8, 16.3%); B1.1.2 (n= 3; 6.1%); B1 (n=2; 4.1%), B1.1.25 (n= 2; 4.1%), B1.1.10 (n=1, 2.1%); and B1.1.70 (n=1, 2.1%). Viral isolates B1.1 and B1.1 with 75% matching to the parent B1.1 were analysed together as viral isolates of the B1.1 lineage.

**NC: cannot be calculated

Abbreviations CI: confidence intervals; OR: odds ratio

Table 4 Univariate and multivariate logistic regression analysis of baseline variables associated with the achievement of the study primary endpoint. In the analysis patients enrolled in the ACHIEVE trial and concurrent standard-of-care comparators are analysed together.

Variable	Incidence of primary endpoint		Univariate analysis		Multivariate analysis	
	No (total=36)	Yes (total=144)	OR (95% CIs)	P- Value	OR (95% CIs)	P- Value
Clarithromycin treatment, n (%)	12 (33.3)	78 (54.2)	2.36 (1.09-5.09)	0.039	3.30 (1.10-9.87)	0.033
CCI, mean (SD)	3.30 (2.50)	1.84 (2.07)	0.77 (0.66-0.89)	0.001	*	
Admission APACHE II score, mean (SD)	7.52 (3.18)	4.82 (3.67)	0.82 (0.75-0.92)	<0.0001	*	
Admission SOFA score, mean (SD)	2.60 (1.55)	0.99 (1.03)	0.39 (0.27-0.54)	<0.0001	0.38 (0.25-0.59)	<0.0001
Admission PSI, mean (SD)	86.8 (27.4)	58.3 (24.9)	0.96 (0.95-0.97)	<0.0001	0.96 (0.94-0.98)	0.001
Lymphocytes/mm ³ , mean (SD)	1052.8 (581.8)	1299.9 (575.3)	1.01 (1.00-1.02)	0.023	*	
Hypertension, n (%)	18 (50.0)	45 (31.3)	0.45 (0.21-0.95)	0.037	*	
Coronary heart disease, n (%)	7 (19.4)	7 (4.9)	0.21 (0.07-0.65)	0.009	*	
Atrial fibrillation, n (%)	6 (16.7)	1 (0.7)	0.04 (0.00-0.30)	<0.0001	*	
CRP, mg/l, mean (SD)	104.9 (115.8)	58.2 (68.4)	0.99 (0.99-0.99)	0.005	*	

*variable did not enter the equation after three steps of the multivariate model

Abbreviations APACHE: acute physiology and chronic health evaluation; CCI: Charlson's comorbidity index; CI: confidence interval; CRP: C-reactive protein; OR: odds ratio; PSI: pneumonia severity index; SOFA: sequential organ failure assessment

***E* gene (Cts)**

***E* gene (copies)**

***RdRp* gene (Cts)**

***RdRp* gene (copies)**

A) IFN γ *C.albicans*-stimulation for 5 days (Th1)

B) IL-6 *C.albicans*-stimulation for 5 days (Th2)

C) *E* gene detection at EOT

D) *RdRp* gene detection at EOT

CRP

TNF α

IL-6

IL-10